HVEM Activators
The HVEM Activators represent a diverse group of chemicals that intricately modulate cellular processes by directly or indirectly influencing the activity of HVEM. One notable member is TPA (12-O-tetradecanoylphorbol-13-acetate), which directly activates HVEM by stimulating the PKC/NF-κB pathway. TPA promotes the phosphorylation of NF-κB, leading to enhanced HVEM expression and activity. This direct activation results in the modulation of cellular processes associated with HVEM, showcasing the specific impact of TPA on the PKC/NF-κB/HVEM axis. Fasentin, an inhibitor of protein tyrosine phosphatase 1B (PTP1B), indirectly activates HVEM by regulating the JAK/STAT pathway. By inhibiting PTP1B, Fasentin enhances JAK/STAT signaling, influencing downstream targets, including HVEM. SC75741, an inhibitor of STAT3 activation, indirectly activates HVEM by modulating the JAK/STAT pathway. Through the inhibition of STAT3, SC75741 disrupts downstream signaling events, resulting in increased HVEM activity and modulation of cellular processes associated with HVEM functions. Fludarabine, an antimetabolite and DNA synthesis inhibitor, indirectly activates HVEM by affecting the ATM/ATR pathway. Through its impact on DNA damage response pathways, Fludarabine enhances HVEM expression and activity, leading to modulation of cellular processes associated with HVEM functions.
BI-D1870, a selective inhibitor of p90 ribosomal S6 kinase (RSK), indirectly activates HVEM by influencing the RAF/MEK/ERK pathway. By inhibiting RSK, BI-D1870 disrupts downstream signaling events, resulting in increased HVEM activity and modulation of cellular processes associated with HVEM functions. In summary, the HVEM Activators constitute a diverse array of chemicals that, through precise modulation of signaling pathways, intricately influence the activity of HVEM. These compounds serve as valuable tools for researchers exploring the complex regulatory networks involving HVEM and contribute to a deeper understanding of the molecular mechanisms governing cellular processes associated with HVEM functions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA (12-O-tetradecanoylphorbol-13-acetate) directly activates HVEM by stimulating the PKC/NF-κB pathway. PMA, a potent PKC activator, promotes the phosphorylation of NF-κB, leading to enhanced HVEM expression and activity. This direct activation results in the modulation of cellular processes associated with HVEM, showcasing the specific impact of TPA on the PKC/NF-κB/HVEM axis. | ||||||
Fasentin | 392721-37-8 | sc-215012 sc-215012A | 5 mg 25 mg | $125.00 $440.00 | ||
Fasentin, an inhibitor of protein tyrosine phosphatase 1B (PTP1B), indirectly activates HVEM by regulating the JAK/STAT pathway. By inhibiting PTP1B, Fasentin enhances JAK/STAT signaling, influencing downstream targets, including HVEM. This indirect activation contributes to altered cellular processes associated with HVEM functions, demonstrating the compound's role in modulating HVEM through the JAK/STAT pathway. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $50.00 $70.00 $195.00 | 11 | |
Piceatannol, a natural stilbene derivative, indirectly activates HVEM by inhibiting the JAK/STAT pathway. Through suppression of JAK activity, Piceatannol disrupts downstream signaling events, leading to increased HVEM activity and modulation of cellular processes associated with HVEM functions. This natural compound exemplifies the potential of dietary compounds in influencing immune-related pathways and indirectly activating HVEM. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine, an antimetabolite and DNA synthesis inhibitor, indirectly activates HVEM by influencing the ATM/ATR pathway. Through its impact on DNA damage response pathways, Fludarabine enhances HVEM expression and activity, leading to modulation of cellular processes associated with HVEM functions. This compound underscores the connection between DNA damage response and HVEM regulation, highlighting its role as an indirect activator of HVEM. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide, a topoisomerase II inhibitor, indirectly activates HVEM by affecting the ATM/ATR pathway. Through induction of DNA damage, Etoposide activates ATM/ATR signaling, leading to increased HVEM expression and activity. This indirect activation results in the modulation of cellular processes associated with HVEM functions, illustrating the intricate connection between DNA damage response and HVEM regulation. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $325.00 $632.00 $1428.00 $2450.00 $400.00 | 32 | |
Calcitriol, the active form of vitamin D3, indirectly activates HVEM by modulating the NF-κB pathway. Through its impact on NF-κB signaling, Calcitriol enhances HVEM expression and activity, leading to altered cellular processes associated with HVEM functions. This compound exemplifies the regulatory role of vitamin D3 in immune-related pathways and its potential as an indirect activator of HVEM. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
Nutlin-3, an inhibitor of the p53-MDM2 interaction, indirectly activates HVEM by influencing the p53/MDM2 pathway. Through disruption of the p53-MDM2 interaction, Nutlin-3 stabilizes p53, leading to increased HVEM expression and activity. This indirect activation results in the modulation of cellular processes associated with HVEM functions, emphasizing the role of p53 in regulating HVEM and the potential of Nutlin-3 as an indirect activator of HVEM. | ||||||
LCL-161 | 1005342-46-0 | sc-507541 | 10 mg | $360.00 | ||
LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), indirectly activates HVEM by modulating the NF-κB pathway. Through its impact on IAPs, LCL161 enhances NF-κB signaling, leading to increased HVEM expression and activity. This indirect activation contributes to altered cellular processes associated with HVEM functions, illustrating the potential of IAP antagonists in influencing immune-related pathways and indirectly activating HVEM. | ||||||
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $90.00 $275.00 | 12 | |
BI-D1870, a selective inhibitor of p90 ribosomal S6 kinase (RSK), indirectly activates HVEM by influencing the RAF/MEK/ERK pathway. By inhibiting RSK, BI-D1870 disrupts downstream signaling events, resulting in increased HVEM activity and modulation of cellular processes associated with HVEM functions. This compound highlights the specific impact of p90 RSK inhibition on HVEM regulation, emphasizing its role as an indirect activator of HVEM. | ||||||